Idelalisib
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis
Conditions
Amyloidosis
Trial Timeline
Jan 1, 2016 → Mar 27, 2017
NCT ID
NCT02590588About Idelalisib
Idelalisib is a phase 2 stage product being developed by Gilead Sciences for Amyloidosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02590588. Target conditions include Amyloidosis.
What happened to similar drugs?
0 of 12 similar drugs in Amyloidosis were approved
Approved (0) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03568929 | Pre-clinical | Completed |
| NCT02739360 | Approved | Terminated |
| NCT02928510 | Pre-clinical | Terminated |
| NCT02536300 | Phase 3 | Terminated |
| NCT02590588 | Phase 2 | Terminated |
| NCT02242045 | Phase 1 | Completed |
| NCT01539291 | Phase 3 | Terminated |
| NCT01393106 | Phase 2 | Completed |
| NCT01282424 | Phase 2 | Completed |
| NCT01306643 | Phase 1/2 | Completed |
| NCT01090414 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Amyloidosis